138840-91-2

Upstream product

• 90-02-8 salicylaldehyde 
• 99-91-2 para-chloroacetophenone 
• 89-95-2 2-methyl-benzyl alcohol 
• 132971-93-8 2'-hydroxy-4-chlorochalcone 
• 132971-93-8 (E)-1-(4-chlorophenyl)-3-(2-hydroxyphenyl)prop-2-en-1-one 

Downstream Products

• 108290-21-7 2-(4-chlorophenyl)pyrazolo<1,5-c><1,3>benzoxazin-5-one 
• 138841-00-6 2-(4-Chloro-phenyl)-5-oxa-3,3a-diaza-cyclopenta[a]naphthalene-4-thione 
• 138840-97-8 2-(4-Chloro-phenyl)-1,9b-dihydro-5-oxa-3,3a-diaza-cyclopenta[a]naphthalene-4-thione 
• 38371-80-1 2-[5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-phenol 
• 138840-94-5 2-(4-Chloro-phenyl)-1,9b-dihydro-5-oxa-3,3a-diaza-cyclopenta[a]naphthalen-4-one 

Relevant academic research and scientific papers

Synthesis of some novel 2,3,4,8,9-pentahydro-7-(4-haloaryl)-pyrazolo[5,1-e] benzo[1,5]oxazocines and 2,3(erythro), 7,8-tetrahydro-2-aryl-3-(4-fluoro-3- methylbenzoyl)-6-(4-haloaryl)pyrazolo[5,1-d] benzo[1,4]oxazepines via solid-liquid PTC

In this communication, a simple and straightforward procedure for the heterocyclization of 1H-4,5-dihydro-3-(4-haloaryl)-5-substituted phenylpyrazoles (4) with 1-bromo-3-chloropropane and 2,3-dibromo-1-(4-fluoro-3-methylphenyl)-3- phe- nylpropanone affording 2,3,4,8,9-pentahydro-7-(4-haloaryl)pyrazolo[5,1-e] benzo[1,5] oxazocines 5 and regioselective synthesis of 2,3(erythro),7,8- tetrahydro-2- aryl-3-(4-fluoro-3-methylbenzoyl)-6-(4-halophenyl)pyrazolo[5,1-d] benzo[1,4]oxa- zepines 6, respectively, via solid-liquid PTC is reported. All the synthesized compounds have been characterized on the basis of their spectral studies (IR, PMR, and MS) and analytical data. Copyright Taylor & Francis Group, LLC.

Novel isoniazid-spirooxindole derivatives: design, synthesis, biological evaluation, in silico ADMET prediction and computational studies

In the present scenario, the Synthesis of new and desired antimycobacterial agent has an eternal demand to resist Mycobacterium tuberculosis (MTB). The design and identification of new molecules for the treatment of tuberculosis is an important task in organic as well as medicinal chemistry research. In the present study, we have reported the combination of the desired compound using two versatile and significant moieties, isoniazid and spirooxindole derivatives. A series of novel isoniazid-spirooxindole hybrid molecules (6a-6ao) were designed, synthesized, and well-characterized by various spectroscopic methods. We have evaluated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv (MTB) strain and MDR-TB. Among them, Compound 6ab was found to be the most effective compare to other compounds. ADMET-related descriptors were to be calculated of all the compounds to predict the pharmacokinetic properties for the selection of the effective and bioavailable compounds. In addition, molecular docking and molecular dynamics studies reveal that the binding modes of all the compounds in the active site of isoniazid-resistant enoyl-ACP(COA) reductase, which helped to establish a structural basis of inhibition of Mycobacterium tuberculosis.

Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors

Based on our recently reported selective hMAO-A inhibitors, on which, the intramolecular cyclization led to a very interesting change of isoform selectivity. A series of selective hMAO-B inhibitors (3a-3u) with novel scaffold of tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one were designed and synthesized. Compound 3u (IC50 = 221 nM) exhibited the best inhibitory activity and isoform selectivity against hMAO-B, superior to selegiline (IC50 = 321 nM), which is a commercial selective hMAO-B inhibitor used to Parkinson's disease. Modeling study indicated that the selectivity of our compounds to hMAO-B is determined by at least two residues, i.e., Ile 199 and Cys 172 (or corresponded Phe 208 and Asn 181 of hMAO-A). These data support further studies to assess rational design of more efficiently selective hMAO-B inhibitors.

Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors

Thirty seven novel 2-pyrazoline-1-ethanone derivatives were designed, synthesized and evaluated as selective hMAO inhibitors. Among them, compounds 7h (IC50 = 2.40 μM) and 12c (IC50 = 2.00 μM) exhibited best inhibitory activity and selectivity against hMAO-A, surpassing that of the positive control Clorgyline (IC50 = 2.76 μM). Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3) > piperidinyl (4) > morpholinyl (5) > imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity. Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively. In addition, the substituent at C3 position of 2-pyrazoline with the N1 acetyl has little effect on MAO-A inhibitory activity. These data support further studies to assess rational design of more efficiently selective hMAO inhibitors in the future.

Synthesis and spectral studies of some novel 2,5,9,10-tetrahydro[7,8-g]benzo-8-arylpyrazolo[4,5-e][1,5-b]benzoxazon ine via phase transfer catalysis

Treatment of 1H-4,5-dihydro-3-aryl-5-(2-hydroxyaryl)pyrazole with o-dibromoxylene under liquid-liquid phase transfer catalytic conditions using tetra-n-butylammonium hydrogen sulphate or [18]-crown-6 as PT catalyst, benzene/chloroform as organic phase and 50% aqueous potassium hydroxide as second phase, afforded novel 2,5,9,10-tetrahydro[7,8-g]benzo-8-arylpyrazolo[4,5-e][1,5-b]benzoxazon ines.

Structure-activity relationship studies of novel pyrazolo[1,5-c][1,3]benzoxazines: Synthesis and benzodiazepine receptor affinity

Some 2-arylpyrazolo[1,5-c][1,3]benzoxazin-5-ones 1 and 5 oxopyrazolo[1,5-c][1,3]benzoxazin-2-carboxylates 2 were prepared and biologically evaluated for their binding at benzodiazepine receptor (BZR) in rat cortical membranes. Structure-activity relations